Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sugita Ace Co Ltd
TSE:7635
|
JP |
|
Benitec Biopharma Inc
NASDAQ:BNTC
|
US |
|
Svolder AB
STO:SVOL B
|
SE |
|
O
|
Origin Enterprises PLC
ISEQ:OIZ
|
IE |
|
Liberty Media Corp
NASDAQ:LSXMA
|
US |
|
Storskogen Group AB (publ)
STO:STOR B
|
SE |
|
G
|
Grupo Clarin SA
BCBA:GCLA
|
AR |
|
Creative Vistas Inc
OTC:CVAS
|
CA |
|
IIFL Wealth Management Ltd
NSE:IIFLWAM
|
IN |
|
VIP Clothing Ltd
NSE:VIPCLOTHNG
|
IN |
|
American Lithium Corp
XTSX:LI
|
CA |
|
Lincoln Educational Services Corp
NASDAQ:LINC
|
US |
Biotron Ltd
Inventory
Biotron Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Inventory
$21.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Inventory
$6.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Inventory
AU$8.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
45%
|
CAGR 10-Years
20%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Inventory
AU$37.1m
|
CAGR 3-Years
64%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
